What Facts Should You Know About Natera (NTRA)?

Shares of Mid-cap life sciences company Natera moved 16.93% this afternoon, and are now trading at $49.51 per share. On the other hand, the average analyst target price for the stock is $72.

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally.

Natera investors should be aware of the below:

The company has a net profit margin of -70.3%, compared to its operating margins of -0.69%. Its Revenues have a year-on-year growth rate of 33.2%, compared to a YoY growth rate of 0.0% for its earnings.

Based on its trailing earning per share of -5.89, Natera has a trailing 12 month Price to Earnings (P/E) ratio of -8.41

Its Price to Book (P/B) ratio is 11.74

2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
EPS -$4.96 -$2.66 -$1.60 -$2.06 -$2.55
EPS Growth -86.0% -67.0% 22.0% 19.0% n/a
Shares Outstanding (k) 95,140 86,223 78,005 62,082 54,040
Shares Growth 10.0% 11.0% 26.0% 15.0% n/a
Net Income (k) -$471,700 -$229,743 -$124,827 -$128,154 -$137,628
Net Income Growth -105.3% -84.0% 2.6% 6.9% n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.